Transdermal Prostaglandin E1 Patch for Ocular Ischemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic ocular ischemic conditions, such as ischemic optic neuropathy and retinopathy, require frequent and invasive intravenous administration of prostaglandin E1, which is challenging for patients and may lead to systemic side effects like hypotension, and there is a need for a more convenient and effective transdermal delivery method.
Innovation Solution
A transdermal preparation containing prostaglandin E1, applied to the skin or nasal mucous membranes, using a suitable vehicle like a cream or patch, to achieve anti-ischemic effects in the ocular district without the need for intravenous administration, enhancing blood flow and treating conditions like high myopia, macular degeneration, glaucoma, and diabetic retinopathy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intravenous administration of prostaglandin E1 is used for chronic ocular ischemic conditions, then anti-ischemic effects are achieved, but frequent hospital visits and invasive treatment are required
Solution Approach 1:
The patent introduces a transdermal patch as an intermediary delivery system that facilitates prostaglandin E1 transfer from the application site to the ocular district through skin penetration, eliminating the need for frequent intravenous administrations and hospital visits while maintaining therapeutic effectiveness
Solution Approach 2:
The patent replaces the mechanical intravenous injection system with a transdermal delivery system that utilizes skin permeation mechanisms, allowing continuous drug delivery through the skin barrier without requiring invasive procedures or frequent medical interventions
2Reliability
If intravenous administration of prostaglandin E1 is used, then anti-ischemic effects are achieved, but systemic side effects like hypotension occur
Solution Approach 1:
The patent applies prostaglandin E1 locally to the skin surface through transdermal patch, utilizing the skin's selective permeability to allow drug entry while limiting systemic distribution, thereby achieving ocular ischemia treatment with reduced systemic side effects compared to intravenous administration
3Reliability
If intravenous administration is used for chronic treatment, then therapeutic effect is maintained, but patient convenience is reduced
Solution Approach 1:
The transdermal patch enables patients to self-administer the treatment by simply applying the patch to their skin, eliminating the need for frequent hospital visits and intravenous procedures, thereby significantly improving patient convenience and quality of life while maintaining therapeutic effectiveness
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The transdermal administration of prostaglandin E1 effectively increases ocular blood flow, providing comparable anti-ischemic effects to intravenous treatment, reducing the frequency of administration and minimizing side effects, allowing patients to self-apply the treatment and avoid frequent hospital visits.
Implementation Method 1
The invention concerns the use of prostaglandin E1 in trans-dermal application for the treatment of ocular ischemia
Implementation Method 2
prostaglandin E1 effectively increases ocular blood flow, providing comparable anti-ischemic effects to intravenous treatment
Data Source
AI summary
The invention concerns the use of a preparation based on prostaglandin E1 (PGE1 as active ingredient in a carrier suitable for administration on the skin or on the mucous membranes, for the treatment by the transdermal or transmucosal route of acute or chronic ophthalmic pathologies of an ischemic nature, and in general for the treatment of ophthalmic pathologies involving at least in part an ischemic mechanism of the ocular district. By applying PGE1, on the skin, particularly in the form of a cream, it is possible to avoid the drawbacks of the intravenous administration of the drug, while still maintaining a comparable level of absorption of the drug in the ocular district. By suitably modulating the dosage, it is possible to obtain in the eye, by the cutaneous administration of PGE1, the same clinical results that can be obtained by intravenous administration.